Cargando…

Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study

The poor prognosis of acute T‐cell lymphoblastic leukemia (T‐ALL) and T‐cell lymphoblastic lymphoma (T‐LBL) in older adults and patients with relapsed/refractory illness is an unmet clinical need, as there is no defined standard of care and there are few treatment options. Abnormally elevated CD38 e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boissel, Nicolas, Chevallier, Patrice, Doronin, Vadim, Griskevicius, Laimonas, Maschan, Alexey, McCloskey, James, Rambaldi, Alessandro, Rossi, Giuseppe, Sokolov, Andrey, Wartiovaara‐Kautto, Ulla, Oprea, Corina, Abbadessa, Giovanni, Gosselin, Alice, Macé, Sandrine, Thomas, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894690/ https://www.ncbi.nlm.nih.gov/pubmed/35106962 http://dx.doi.org/10.1002/cam4.4478

Ejemplares similares

P501: ISATUXIMAB PLUS CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA (ISAKIDS): INTERIM EFFICACY ANALYSIS
por: Baruchel, André, et al.
Publicado: (2023)

A minor role of asparaginase in predisposing to cerebral venous thromboses in adult acute lymphoblastic leukemia patients
por: Roininen, Saara, et al.
Publicado: (2017)

Enrichment of cancer-predisposing germline variants in adult and pediatric patients with acute lymphoblastic leukemia
por: Douglas, Suvi P. M., et al.
Publicado: (2022)

Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age
por: Rank, Cecilie U., et al.
Publicado: (2020)

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2019)

Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia
por: Koprivnikar, Jamie, et al.
Publicado: (2017)

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
por: Mikhael, Joseph, et al.
Publicado: (2021)

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
por: Martin, Thomas G., et al.
Publicado: (2019)

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study
por: Sunami, Kazutaka, et al.
Publicado: (2020)

Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study
por: Boissel, Nicolas, et al.
Publicado: (2023)

Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase
por: Boissel, Nicolas, et al.
Publicado: (2015)

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
por: Lussana, Federico, et al.
Publicado: (2021)

Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a population-based study
por: Norvilas, Rimvydas, et al.
Publicado: (2021)

‘Metaphyseal dysplasia without hypotrichosis’ can present with late-onset extraskeletal manifestations
por: Vakkilainen, Svetlana, et al.
Publicado: (2020)

Role of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia
por: Lussana, Federico, et al.
Publicado: (2014)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Fibrinolytic Activity and Platelet Function in Subjects with Obstructive Sleep Apnoea and a Patent Foramen Ovale: Is There an Option for Prevention of Ischaemic Stroke?
por: Reggiani, Monica, et al.
Publicado: (2012)

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma
por: Hulin, Cyrille, et al.
Publicado: (2021)

PB2005: AZACITIDINE IN COMBINATION WITH 14-DAY VENETOCLAX VERSUS AZACITIDINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS-2 IN CLINICAL PRACTICE SETTING
por: Žučenka, Andrius, et al.
Publicado: (2023)

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
por: Gibson, Amber, et al.
Publicado: (2021)

Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
por: Maese, Luke, et al.
Publicado: (2022)

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
por: Ocio, Enrique M., et al.
Publicado: (2023)

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients
por: Fau, Jean‐Baptiste, et al.
Publicado: (2020)

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2022)

Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
por: Savoy, J. Michael, et al.
Publicado: (2018)

Isatuximab: A Review of Its Use in Multiple Myeloma
por: Frampton, James E.
Publicado: (2021)

Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis
por: Kim, Rathana, et al.
Publicado: (2023)

Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia who have been treated with blinatumomab
por: Mikhailova, Ekaterina, et al.
Publicado: (2020)

Acute lymphoblastic leukemia
por: Schrappe, Martin
Publicado: (2018)

Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma
por: Cooper, Todd M
Publicado: (2007)

Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma
por: Yu, Hui, et al.
Publicado: (2019)

A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
por: Carlo‐Stella, Carmelo, et al.
Publicado: (2022)

Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells
por: Grain, Audrey, et al.
Publicado: (2023)

Case report: Olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia
por: Ding, Jianghua, et al.
Publicado: (2023)

Correction to: Isatuximab: A Review of Its Use in Multiple Myeloma
por: Frampton, James E.
Publicado: (2021)

Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
por: Shen, Fei, et al.
Publicado: (2022)

Ultrastructural changes in cristae of lymphoblasts in acute lymphoblastic leukemia parallel alterations in biogenesis markers
por: Singh, Ritika, et al.
Publicado: (2021)

High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL
por: Cabannes-Hamy, Aurélie, et al.
Publicado: (2022)

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
por: Mikhael, Joseph, et al.
Publicado: (2020)

Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells
por: Mikhailova, Ekaterina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ck189cfscld4ohpju65mblbavq